Daniil Gataulin
Stock Analyst at Chardan Capital
(4.15)
# 1,523
Out of 4,457 analysts
77
Total ratings
43.3%
Success rate
16.7%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Daniil Gataulin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| OCUL Ocular Therapeutix | Maintained: Buy | $21 → $23 | $9.90 | +132.32% | 3 | Jun 25, 2026 | |
| IRD Opus Genetics | Maintained: Buy | $11 → $13 | $4.06 | +220.20% | 3 | Jun 17, 2026 | |
| CRVO CervoMed | Reiterated: Buy | $21 | $3.15 | +566.67% | 7 | May 17, 2026 | |
| MGTX MeiraGTx Holdings | Reiterated: Buy | $36 → $35 | $12.54 | +179.11% | 2 | May 14, 2026 | |
| OCS Oculis Holding AG | Reiterated: Buy | $51 → $53 | $13.09 | +304.89% | 3 | May 12, 2026 | |
| FBRX Forte Biosciences | Reiterated: Buy | $61 | $21.38 | +185.31% | 3 | May 11, 2026 | |
| KOD Kodiak Sciences | Upgraded: Buy | $14 → $61 | $37.74 | +61.63% | 6 | May 11, 2026 | |
| CGTX Cognition Therapeutics | Reiterated: Buy | $8 → $4 | $1.09 | +266.97% | 3 | May 8, 2026 | |
| OCGN Ocugen | Reiterated: Buy | $5 → $7 | $1.67 | +319.16% | 8 | May 7, 2026 | |
| ZURA Zura Bio | Reiterated: Buy | $10 → $11 | $5.63 | +95.38% | 4 | May 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $29 | $14.11 | +105.53% | 6 | May 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $37 | $47.39 | -21.92% | 8 | May 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $52 | $11.83 | +339.56% | 8 | Jan 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $3 → $1 | $1.69 | -40.83% | 6 | Jan 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $16 | $5.57 | +187.25% | 1 | Dec 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $19 | $4.22 | +350.77% | 1 | Dec 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $0.195 | - | 2 | Jul 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $0.0801 | n/a | 1 | Jun 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $13.24 | n/a | 2 | Feb 15, 2023 |
Ocular Therapeutix
Jun 25, 2026
Maintained: Buy
Price Target: $21 → $23
Current: $9.90
Upside: +132.32%
Opus Genetics
Jun 17, 2026
Maintained: Buy
Price Target: $11 → $13
Current: $4.06
Upside: +220.20%
CervoMed
May 17, 2026
Reiterated: Buy
Price Target: $21
Current: $3.15
Upside: +566.67%
MeiraGTx Holdings
May 14, 2026
Reiterated: Buy
Price Target: $36 → $35
Current: $12.54
Upside: +179.11%
Oculis Holding AG
May 12, 2026
Reiterated: Buy
Price Target: $51 → $53
Current: $13.09
Upside: +304.89%
Forte Biosciences
May 11, 2026
Reiterated: Buy
Price Target: $61
Current: $21.38
Upside: +185.31%
Kodiak Sciences
May 11, 2026
Upgraded: Buy
Price Target: $14 → $61
Current: $37.74
Upside: +61.63%
Cognition Therapeutics
May 8, 2026
Reiterated: Buy
Price Target: $8 → $4
Current: $1.09
Upside: +266.97%
Ocugen
May 7, 2026
Reiterated: Buy
Price Target: $5 → $7
Current: $1.67
Upside: +319.16%
Zura Bio
May 7, 2026
Reiterated: Buy
Price Target: $10 → $11
Current: $5.63
Upside: +95.38%
May 6, 2026
Reiterated: Buy
Price Target: $29
Current: $14.11
Upside: +105.53%
May 5, 2026
Reiterated: Buy
Price Target: $37
Current: $47.39
Upside: -21.92%
Jan 28, 2026
Reiterated: Buy
Price Target: $52
Current: $11.83
Upside: +339.56%
Jan 2, 2026
Maintained: Hold
Price Target: $3 → $1
Current: $1.69
Upside: -40.83%
Dec 23, 2025
Initiated Coverage: Buy
Price Target: $16
Current: $5.57
Upside: +187.25%
Dec 23, 2025
Initiated Coverage: Buy
Price Target: $19
Current: $4.22
Upside: +350.77%
Jul 17, 2025
Downgraded: Hold
Price Target: n/a
Current: $0.195
Upside: -
Jun 13, 2025
Maintained: Hold
Price Target: n/a
Current: $0.0801
Upside: n/a
Feb 15, 2023
Downgraded: Hold
Price Target: n/a
Current: $13.24
Upside: n/a